Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
Director departure
Appointed director
Provention Bio, Inc. (PRVB) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/27/2023 8-K Quarterly results
03/13/2023 8-K Amended existing or entered into new employment agreement with an officer, Appointed a new director
Docs: "Execution Version AGREEMENT AND PLAN OF MERGER among SANOFI S.A., ZEST ACQUISITION SUB, INC. and PROVENTION BIO, INC. Dated as of March 12, 2023",
"AMENDED AND RESTATED BYLAWS OF PROVENTION BIO, INC.",
"SECOND AMENDMENT TO FIRST AMENDED EMPLOYMENT AGREEMENT",
"SECOND AMENDMENT TO EMPLOYMENT AGREEMENT",
"SECOND AMENDMENT TO FIRST AMENDED EMPLOYMENT AGREEMENT",
"Sandrine Guendoul"
02/13/2023 8-K Quarterly results
02/02/2023 8-K Quarterly results
01/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Investor Contact:"
12/06/2022 8-K Quarterly results
11/17/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
08/31/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Investor Contact:"
08/04/2022 8-K Quarterly results
Docs: "Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update"
07/08/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/21/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
02/24/2022 8-K Quarterly results
02/22/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
01/27/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
11/22/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway"
11/04/2021 8-K Quarterly results
Docs: "Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update",
"Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer Andrew Drechsler to Retire as Chief Financial Officer in December"
08/05/2021 8-K Quarterly results
Docs: "Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update"
07/06/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Provention Bio Receives Complete Response Letter to Biologics License Application for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-risk Individuals"
05/27/2021 8-K Quarterly results
05/25/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
04/08/2021 8-K Quarterly results
02/26/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
01/15/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy